While the STAR trial showed significant reductions in myopia progression, including over 50% in fast-progressing children, the FDA requires additional evidence to support US approval. Additionally, a ...

Diabetic Macular Edema | clinical | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

This study indicated that by analyzing the data of one of the most extensive GA patient cohorts in the Nordic countries, it established a data set on the long-term treatment-naive GA growth dynamics.

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim. In an interview with Esther Lee Kim, MD, from Orange County Retina in ...

Broader perspective for the treatment approach on retinal neovascular diseases ...

The triad of inflammation, neuropathy, and vasculopathy plays a key role in the development and progression of diabetic retinopathy (DR). Dr. Varun Chaudhary and Dr. Patrick Bussfeld, discuss how ...

In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success. As ophthalmologists and retina ...

New treatment options enhance patient visual outcomes and reduce treatment burdens. The PHOTON study (NCT04429503) evaluated the safety and efficacy of high-dose aflibercept (Eylea; Regeneron ...

A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, ...

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials. Breye Therapeutics announced the successful ...

Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...